Fathom Therapeutics: Funding, Investors & Team (Sep 2026)
Fathom Therapeutics, previously known as Atommap, is a biotechnology company focused on designing therapeutic molecules through computational drug discovery approaches. The company develops models that simulate biomolecular and protein motion to better understand how proteins behave and interact, enabling the identification of new therapeutic strategies. Its platform combines generative design, predictive modeling, and computational assays to create and evaluate molecular candidates for their binding affinity and functional effects. By leveraging these simulations, it supports drug discovery processes such as hit identification, lead optimization, and the design of targeted molecules, including degraders and molecular glues. The company also collaborates with partners by providing molecular designs, predictive insights, and co-development opportunities for advancing therapeutic candidates.
Fathom Therapeutics has raised $47.0M across 1 funding round on record, the most recent a Series A of $47.0M announced in Apr 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Fathom Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Fathom Therapeutics Funding Rounds
Fathom Therapeutics Founders and Leadership Team
Contact details for the Fathom Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Fathom Therapeutics Funding Compared to Other Biotechnology Startups
Fathom Therapeutics' latest round of $47.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Fathom Therapeutics in Biotechnology and New York
Companies Similar to Fathom Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Fathom Therapeutics Funding FAQs
What does Fathom Therapeutics do?
Fathom Therapeutics, previously known as Atommap, is a biotechnology company focused on designing therapeutic molecules through computational drug discovery approaches. The company develops models that simulate biomolecular and protein motion to better understand how proteins behave and interact, enabling the identification of new therapeutic strategies. Its platform combines generative design, predictive modeling, and computational assays to create and evaluate molecular candidates for their binding affinity and functional effects. By leveraging these simulations, it supports drug discovery processes such as hit identification, lead optimization, and the design of targeted molecules, including degraders and molecular glues. The company also collaborates with partners by providing molecular designs, predictive insights, and co-development opportunities for advancing therapeutic candidates.
How much funding has Fathom Therapeutics raised?
Fathom Therapeutics has raised $47.0M across 1 round on record. The most recent is a Series A of $47.0M announced in Apr 2026.
When did Fathom Therapeutics last raise funding?
Fathom Therapeutics' most recent funding round on record is a Series A of $47.0M, announced in Apr 2026.
Who founded Fathom Therapeutics?
FundedIQ lists Huafeng Xu (Founder) at Fathom Therapeutics.
Where is Fathom Therapeutics headquartered?
Fathom Therapeutics is based in New York, New York, United States.
How many employees does Fathom Therapeutics have?
Fathom Therapeutics is in the 11-50 employee band.
How does Fathom Therapeutics' funding compare to other Biotechnology startups?
Fathom Therapeutics' latest round of $47.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Fathom Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Fathom Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.